HONG KONG, Feb 3, 2023 - (ACN Newswire) - Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, announces that the phase I clinical trial of OT-202 (tyrosine kinase inhibitor), a class I new drug developed by the Company for the treatment of dry eye, has been completed successfully.
The phase I clinical trial of OT-202 was designed as a randomized, double-masked, placebo-controlled clinical trial on the safety, tolerance and pharmacokinetic properties of its single/multiple administration on healthy adult subjects in China.
Mr. Ye LIU, the Executive Director and CEO of Ocumension Therapeutics said, "OT-202 (tyrosine kinase inhibitor) is a class I innovative drug developed by the Company for the treatment of moderate to severe dry eye. A total of 30 subjects were enrolled for the phase I clinical trial in China. OT-202 demonstrated good safety and tolerability profile in healthy adult subjects in the phase I clinical trial. Currently, we are in the process of advancing the study for the phase II clinical trial."
The mechanism of action of OT-202 is that the dual-targeted inhibitor of spleen tyrosine kinase (Syk) and vascular endothelial growth factor receptor achieves a synergistic effect in the treatment of dry eye diseases and inhibits the inflammatory response.
More information about Ocumension Therapeutics: https://www.ocumension.com/
Topic: Press release summary
Source: Ocumension Therapeutics
Sectors: BioTech, Healthcare & Pharm
From the Asia Corporate News Network
Copyright © 2023 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.